3 results
The objective of this study is to evaluate the effect of the 4 successive monthly subcutaneous administrations of 30 mg of gevokizumab (in part A) , as well as 60mg (in part B) of the protocol, versus placebo on the reduction of arterial wall…
The objective of the proposed study is to confirm the findings of the dose ranging trial by, primarily, assessing the effect of two doses of CHF6001 on the rate reduction of moderate and severe exacerbations, when added onto maintenance triple…
The objective of the proposed study is to confirm the findings of the dose finding trial by, primarily, assessing the effect of two doses of CHF6001 on the rate reduction of moderate and severe exacerbations, when added onto maintenance triple…